-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026

Reuters·09/30/2026 11:04:15